Newsfeeds Archive - Page 25 of 56

1 minute read

Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released

May 9, 6:29 PM

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.

CYBN

3 minute read

Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More

By Lara Goldstein

May 8, 4:23 PM

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations

CMND

2 minute read

Phase 2 Psilocybin Therapy Trial For Patients With Treatment-Resistant PTSD: Latest Findings

By Lara Goldstein

May 7, 11:52 AM

Cannabis company Creso Pharma (OTCMKTS: COPHF)’s wholly-owned psychedelics subsidiary Halucenex Life Sciences Inc.

COPHF

2 minute read

MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections

By Lara Goldstein

May 5, 2:20 PM

Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business highlights. Numbers show:

MNMD

2 minute read

Amanita Muscaria Mushrooms Are Taking The Lead In Markets As Research Ramps Up

By Lara Goldstein

May 4, 8:33 AM

Amanita Muscaria is the only kind of mushroom currently legal. As its health benefits are regularly being confirmed in studies, demand for related products is rapidly growing.

PLSH

2 minute read

Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction

By Lara Goldstein

May 3, 3:04 PM

Alcohol Use Disorder (AUD) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine (NASDAQ: CMND), the Israel-based company is going at it through its MEAI-based proprietary drug candidate, CMND-100.

CMND

2 minute read

Psychedelics Company Confirms Shares Spinout, Another Fails To File Financials & Gets CTO Issue

By Lara Goldstein

May 3, 7:49 AM

Blackhawk and MindBio Complete Plan Of Arrangement, Shares Spinout

IWINF

3 minute read

EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, ‘Filing A Gap’ In Regulations

By Lara Goldstein

May 2, 7:00 AM

The American Medical Association (AMA) is expected to issue the first code for psychedelic therapy reimbursement, following Tuesday's approval of a joint application submitted by MAPS PBC and COMPASS Pathways (NASDAQ: CMPS).

CMPS

3 minute read

Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More

By Lara Goldstein

May 1, 7:06 PM

Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued

AWKNF

2 minute read

Awakn’s Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion

By Lara Goldstein

April 28, 12:57 PM

The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.

AWKNF